Perspective Therapeutics, Inc. $CATX is Avidity Partners Management LP’s 8th Largest Position

Avidity Partners Management LP grew its position in shares of Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) by 7.2% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 3,210,733 shares of the company’s stock after buying an additional 216,700 shares during the quarter. Perspective Therapeutics accounts for 2.5% of Avidity Partners Management LP’s investment portfolio, making the stock its 8th largest holding. Avidity Partners Management LP’s holdings in Perspective Therapeutics were worth $8,830,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Aigen Investment Management LP purchased a new position in Perspective Therapeutics during the 4th quarter worth $28,000. Russell Investments Group Ltd. raised its position in Perspective Therapeutics by 184.1% during the 3rd quarter. Russell Investments Group Ltd. now owns 8,449 shares of the company’s stock worth $29,000 after buying an additional 5,475 shares during the last quarter. AXQ Capital LP raised its position in Perspective Therapeutics by 24.2% during the 4th quarter. AXQ Capital LP now owns 12,749 shares of the company’s stock worth $35,000 after buying an additional 2,481 shares during the last quarter. Caitong International Asset Management Co. Ltd purchased a new position in Perspective Therapeutics during the 4th quarter worth $42,000. Finally, R Squared Ltd purchased a new position in Perspective Therapeutics during the 4th quarter worth $44,000. Hedge funds and other institutional investors own 54.66% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have commented on CATX. UBS Group upped their price objective on shares of Perspective Therapeutics from $7.00 to $8.00 and gave the stock a “buy” rating in a research report on Wednesday, March 18th. B. Riley Financial upped their price target on shares of Perspective Therapeutics from $11.00 to $13.00 and gave the stock a “buy” rating in a research note on Wednesday, March 18th. HC Wainwright upped their price target on shares of Perspective Therapeutics from $12.00 to $13.00 and gave the stock a “buy” rating in a research note on Monday, March 23rd. Royal Bank Of Canada lowered their price target on shares of Perspective Therapeutics from $18.00 to $14.00 and set an “outperform” rating on the stock in a research note on Tuesday, March 17th. Finally, BTIG Research reaffirmed a “buy” rating and set a $14.00 price target on shares of Perspective Therapeutics in a research note on Tuesday, March 17th. One analyst has rated the stock with a Strong Buy rating and eight have given a Buy rating to the stock. According to data from MarketBeat.com, Perspective Therapeutics has a consensus rating of “Buy” and an average target price of $12.63.

Perspective Therapeutics Stock Down 0.7%

NYSEAMERICAN:CATX opened at $2.95 on Friday. Perspective Therapeutics, Inc. has a fifty-two week low of $1.96 and a fifty-two week high of $6.16. The firm’s fifty day simple moving average is $3.93 and its 200-day simple moving average is $3.77.

Perspective Therapeutics (NYSEAMERICAN:CATX) last posted its quarterly earnings results on Monday, May 11th. The company reported ($0.25) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.04. Perspective Therapeutics had a negative net margin of 17,982.69% and a negative return on equity of 42.33%. The business had revenue of $0.08 million for the quarter, compared to analysts’ expectations of $0.16 million. As a group, analysts forecast that Perspective Therapeutics, Inc. will post -1.13 EPS for the current year.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.